Pfizer Licenses 3SBio’s Bispecific Antibody SSGJ-707 in Global Deal Excluding China
US major Pfizer Inc., (NYSE: PFE) this week entered into a global license agreement with...
Bayer’s Jivi Receives FDA Approval for Pediatric Hemophilia A Treatment
German pharmaceutical giant Bayer AG (ETR: BAYN) announced this week that it has received an...
Alibaba Health Reports Strong 2025 Financial Results with Revenue Hike
China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2025 financial report for the...
CSPC Pharmaceutical’s CPO301 Receives Third FDA Fast Track Designation for NSqNSCLC
China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its EGFR-targeted antibody-drug conjugate (ADC) CPO301...
Merck Sharp & Dohme Initiates Phase III Trial of Ifinatamab Deruxtecan for Esophageal Cancer
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced the first patient dosing in...
Terumo Corporation Acquires WuXi Biologics’ Germany Plant for EUR 150 Million
Japan-based Terumo Corporation (TYO: 4543) has entered into an agreement with China-based Contract Research, Development...
Grand Pharma’s Chengdu RDC Megafactory Secures Class A Radiation Safety License
Grand Pharmaceutical Group Limited (HKG: 0512) has obtained a Class A Radiation Safety License from...
Shanghai Henlius Biotech Doses First Patient in Phase I/III Study of HLX13 for Hepatocellular Carcinoma
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the completion of first patient dosing in a...
Shanghai MicroPort’s Minos Stent Graft Secures Egyptian Marketing Approval
China’s Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has announced that it has received...
Sino Biopharmaceutical’s QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 2.2 drug QP001 (meloxicam) has...
Porton Pharma Partners with Tong Eye on iPSC-Derived RPE Cell Therapies for Ophthalmic Diseases
Chinese CDMO leader Porton Pharma Solutions Ltd. has entered into a strategic partnership with domestic...
InnoCare Pharma Doses First Patient in Phase II/III Trial of TYK2 Inhibitor for Vitiligo
Chinese biotech InnoCare Pharma (HKG: 9969, SHA: 688428) has administered the first patient dose in...
Suzhou’s PegBio Launches Hong Kong IPO Amid Pipeline Progress
Suzhou-based endocrine-metabolism biotech PegBio Co., Ltd. (HKG: 2565) has successfully launched its Hong Kong IPO,...
Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Market Challenges
Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced last week that Lars Fruergaard...
BMS Receives EC Approval for Opdivo-based Perioperative Regimen in NSCLC
Bristol-Myers Squibb (BMS; NYSE: BMY) announced last week that it has received marketing authorization from...
Merck’s Keytruda Meets Primary Endpoint in Phase III Ovarian Cancer Trial
US-based Merck Sharp & Dohme Inc. (MSD; NYSE: MRK) announced positive results from the Phase...
China’s AIM Vaccine Launches Clinical Trials for mRNA Shingles Vaccine in China and US
China-based AIM Vaccine Co., Ltd (HKG: 6660) announced the initiation of clinical trials for its...
FDA Approves Merck’s Welireg for Locally Advanced or Metastatic Pheochromocytoma and Paraganglioma
The US Food and Drug Administration (FDA) announced this week an indication extension approval for...
Innovent Biologics Commences Phase III GLORY-3 Study of Mazdutide for Metabolic Dysfunction-associated Fatty Liver Disease
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the Phase III...
Boehringer Ingelheim and Tempus Forge Multi-Year AI-Driven Oncology Drug Development Partnership
Germany-based pharmaceutical major Boehringer Ingelheim has entered into a multi-year strategic collaboration with Tempus (NASDAQ:...